Table 1 Baseline Characteristics by Age and Sex: A) Male and B) Female

A) Male

Age

18–45

> 45

Total

Placebo

(n = 18)

Quarterly fremanezumab

(n = 18)

Monthly fremanezumab

(n = 20)

Placebo

(n = 28)

Quarterly fremanezumab

(n = 29)

Monthly fremanezumab

(n = 25)

Placebo

(n = 46)

Quarterly fremanezumab

(n= 47)

Monthly fremanezumab

(n= 45)

Monthly migraine days, mean (SD)

12.6 (5.88)

11.9 (5.16)

15.7 (4.90)

14.6 (6.92)

17.1 (5.47)

16.1 (5.32)

13.8 (6.53)

15.1 (5.87)

15.9 (5.08)

Migraine classification, n (%)

 CM

10 (56)

7 (39)

14 (70)

16 (57)

24 (83)

19 (76)

26 (57)

31 (66)

33 (73)

 EM

8 (44)

11 (61)

6 (30)

12 (43)

5 (17)

6 (24)

20 (43)

16 (34)

12 (27)

Migraine preventive medications with inadequate response in the past 10 years, n (%)

 Beta-blockers

10 (56)

6 (33)

10 (50)

14 (50)

15 (52)

16 (64)

24 (52)

21 (45)

26 (58)

 Anticonvulsants

14 (78)

13 (72)

14 (70)

10 (36)

22 (76)

19 (76)

24 (52)

35 (74)

33 (73)

 Tricyclics

7 (39)

10 (56)

6 (30)

11 (39)

13 (45)

14 (56)

18 (39)

23 (49)

20 (44)

 Flunarizine

4 (22)

5 (28)

5 (25)

5 (18)

0

2 (8)

9 (20)

5 (11)

7 (16)

 Candesartan

0

4 (22)

3 (15)

10 (36)

5 (17)

4 (16)

10 (22)

9 (19)

7 (16)

 OnabotulinumtoxinA

8 (44)

2 (11)

3 (15)

9 (32)

12 (41)

10 (40)

17 (37)

14 (30)

13 (29)

 Valproic acid

5 (28)

5 (28)

10 (50)

8 (29)

12 (41)

8 (32)

13 (28)

17 (36)

18 (40)

Number of previous preventive medication classes with inadequate response, n (%)

 2

8 (44)

11 (61)

11 (55)

19 (68)

12 (41)

9 (36)

27 (59)

23 (49)

20 (44)

 3

8 (44)

5 (28)

7 (35)

7 (25)

13 (45)

9 (36)

15 (33)

18 (38)

16 (36)

 4

2 (11)

2 (11)

2 (10)

2 (7)

4 (14)

7 (28)

4 (9)

6 (13)

9 (20)

B) Female

Age

18–45

> 45

Total

Placebo

(n= 103)

Quarterly fremanezumab

(n= 107)

Monthly fremanezumab

(n = 108)

Placebo

(n = 130)

Quarterly fremanezumab

(n = 122)

Monthly fremanezumab

(n = 130)

Placebo

(n = 232)

Quarterly fremanezumab

(n = 229)

Monthly fremanezumab

(n = 238)

Monthly migraine days, mean (SD)

13.7 (6.43)

13.4 (5.76)

13.8 (5.86)

15.1 (5.68)

14.2 (5.33)

13.7 (5.41)

14.5 (6.05)

13.9 (5.54)

13.7 (5.61)

Migraine classification, n (%)

 CM

57 (55)

59 (55)

64 (59)

84 (65)

79 (65)

76 (58)

141 (61)

138 (60)

140 (59)

 EM

45 (44)

48 (45)

44 (41)

46 (35)

43 (35)

54 (42)

91 (39)

91 (40)

98 (77)

Migraine preventive medications with inadequate response in the past 10 years, n (%)

 Beta-blockers

55 (53)

64 (60)

59 (55)

81 (62)

61 (50)

80 (62)

136 (59)

125 (55)

139 (58)

 Anticonvulsants

77 (75)

85 (79)

82 (76)

85 (65)

93 (76)

101 (78)

162 (70)

178 (78)

183 (77)

 Tricyclics

54 (52)

48 (45)

52 (48)

65 (50)

53 (43)

55 (42)

119 (51)

101 (44)

107 (45)

 Flunarizine

21 (20)

18 (17)

22 (20)

29 (22)

18 (15)

16 (12)

50 (22)

36 (16)

38 (16)

 Candesartan

17 (17)

20 (19)

16 (15)

24 (18)

24 (20)

23 (18)

41 (18)

44 (19)

39 (16)

 OnabotulinumtoxinA 

25 (24)

31 (29)

25 (23)

34 (26)

30 (25)

33 (25)

59 (25)

61 (27)

58 (24)

 Valproic acid

29 (28)

25 (23)

27 (25)

41 (32)

44 (36)

47 (36)

70 (30)

69 (30)

74 (31)

Number of previous preventive medication classes with inadequate response, n (%)

 2

49 (48)

49 (46)

53 (49)

66 (51)

68 (56)

60 (46)

115 (50)

117 (51)

113 (47)

 3

36 (35)

36 (34)

43 (40)

31 (24)

31 (25)

39 (30)

67 (29)

67 (29)

82 (34)

 4

18 (17)

21 (20)

12 (11)

32 (25)

22 (18)

29 (22)

50 (22)

43 (19)

41 (17)